Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

[1]  S. Heymans,et al.  Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. , 2020, JACC. Heart failure.

[2]  S. Heymans,et al.  The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial , 2020, European heart journal.

[3]  Amy S. Shah,et al.  Circulating Adhesion Molecules and Associations with HbA1c, Hypertension, Nephropathy, and Retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth (TODAY) Study. , 2020, Pediatric diabetes.

[4]  K. Dickstein,et al.  Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. , 2020, JACC. Heart failure.

[5]  S. Heymans,et al.  Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial , 2020, European journal of heart failure.

[6]  S. O’Rahilly,et al.  GDF15 mediates the effects of metformin on body weight and energy balance , 2019, Nature.

[7]  N. Samani,et al.  The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach , 2019, European journal of heart failure.

[8]  Amogelang R. Raphenya,et al.  Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss , 2019, Nature Metabolism.

[9]  E. Blaak,et al.  Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans , 2019, Diabetologia.

[10]  L. Lind,et al.  In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study , 2019, Diabetologia.

[11]  Long Ma,et al.  Is IL1R1 required for celastrol’s leptin-sensitization and antiobesity effects? , 2019 .

[12]  K. Copps,et al.  IL1R1 is required for celastrol’s leptin sensitization and anti-obesity effects , 2019, Nature Network Boston.

[13]  L. Råstam,et al.  Using a Targeted Proteomics Chip to Explore Pathophysiological Pathways for Incident Diabetes– The Malmö Preventive Project , 2019, Scientific Reports.

[14]  P. Ponikowski,et al.  Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. , 2018, Journal of the American College of Cardiology.

[15]  W. Kraus,et al.  Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. , 2017, JACC. Heart failure.

[16]  A. Kengne,et al.  Correlation of E-selectin concentrations with carotid intima-media thickness and cardio-metabolic profile of mixed ancestry South Africans: a cross-sectional study , 2017, Annals of clinical biochemistry.

[17]  M. Karin,et al.  Inflammation Improves Glucose Homeostasis through IKKβ-XBP1s Interaction , 2016, Cell.

[18]  A. Domínguez-Rodríguez,et al.  Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. , 2014, The American journal of cardiology.

[19]  Caroline Tao,et al.  Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. , 2014, Cell metabolism.

[20]  A. Feldstein,et al.  Lysosomal Cathepsin D contributes to cell death during adipocyte hypertrophy , 2013, Adipocyte.

[21]  S. Kitazawa,et al.  PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. , 2012, Cell metabolism.

[22]  M. Horie,et al.  Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. , 2010, American heart journal.

[23]  Tetsuro Ago,et al.  GDF15, a Cardioprotective TGF-β Superfamily Protein , 2006 .

[24]  J. Sadoshima,et al.  GDF15, a cardioprotective TGF-beta superfamily protein. , 2006, Circulation research.

[25]  A. Morris,et al.  Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes , 2004, Diabetologia.

[26]  M. Domanski,et al.  The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. , 2003, Journal of the American College of Cardiology.

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[28]  F. Zannad,et al.  Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort , 2000, Human Genetics.